Thomas van Sloten from Utrecht University in the Netherlands observes a rising prevalence of dementia among individuals with both Type 1 and Type 2 diabetes. He analyzes the underlying drivers and mitigation strategies, advocating that dementia should be integrated as a core outcome measure in clinical trials for diabetes treatments.
In recent years, the global incidence of dementia has increased significantly among patients with Type 2 Diabetes Mellitus (T2DM). Data indicate that one in every four elderly T2DM patients develops dementia. Moreover, diabetes continues to gain greater weight as a contributing factor, ranking as the fourth most relevant risk factor for dementia onset.
Three core factors primarily drive this trend. First, the dual surge in population aging and diabetes prevalence. The most substantial increase in diabetes rates occurs among those aged 65 and above; the overlap of advanced age and diabetes directly expands the high-risk population base. Second, earlier disease onset extends disease duration from approximately 10 years to over 15 years. Prolonged exposure of the brain to damaging factors such as chronic hyperglycemia and insulin resistance accumulates dementia risk over time. Additionally, declining mortality rates among diabetic patients fully unmask dementia risks that previously remained latent due to early death.
Regarding risk stratification, age at diabetes diagnosis acts as a critical modifier. Individuals diagnosed in midlife (≤ 60 years) face significantly higher dementia risk than those diagnosed in old age. Midlife obesity synergistically compounds risk with diabetes, exacerbating insulin resistance and chronic inflammation to damage cerebral blood vessels and neurons. Shared risk factors including smoking, physical inactivity, high-sugar high-fat diets, hypertension, and low educational attainment also aggravate cognitive impairment through common pathological mechanisms such as vascular injury and oxidative stress.
Notably, patients with Type 1 Diabetes Mellitus (T1DM) also carry elevated dementia risk, with significantly higher all-cause dementia incidence than the general population. This highlights persistent cognitive damage caused by long-term glycemic dysregulation. The core mitigation strategy centers on comprehensive risk control. Studies confirm that when diabetic patients achieve 5 to 7 key targets simultaneously — including optimal HbA1c, BMI, blood pressure, non-smoking status, healthy diet, and regular physical activity (≥ 150 minutes weekly) — their dementia risk approaches that of people without diabetes. This underscores the importance of multidimensional long-term management. Currently, academia advocates shifting research focus from short-term glycemic control to a lifelong health perspective, and promotes incorporating dementia as a mandatory core endpoint in diabetes therapeutic clinical trials.